Title: Pioglitazone Hydrochloride Approved as Concomitant Therapy With Biguanides for Type 2 Diabetes in Japan
|
|
To print: Select File and then Print from your browser's menu Title: Pioglitazone Hydrochloride Approved as Concomitant Therapy With Biguanides for Type 2 Diabetes in Japan |
|
"Pioglitazone Hydrochloride Approved as Concomitant Therapy With Biguanides for Type 2 Diabetes in Japan" NEW YORK -- December 22, 2008 -- An additional indication of concomitant therapy with biguanides has been approved for pioglitazone hydrochloride (Actos) by the Ministry of Health, Labour, and Welfare in Japan, for the treatment of type 2 diabetes. The approval is based on a randomised, double-blind, comparative study, in which the clinical usefulness of biguanides monotherapy was compared with that of biguanides plus pioglitazone hydrochloride. Patients receiving biguanides plus pioglitazone hydrochloride showed a statistically significant difference in improving HbA1C without increasing the risk of hypoglycaemia. Management of type 2 diabetes should also include nutritional counselling, weight reduction as needed, and exercise. SOURCE: Takeda Pharmaceutical Company Limited |
|
Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. Go back This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 2009 P\S\L Consulting Group Inc. All rights reserved. |